Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

4478 - First-line (1L) or second-line (2L) avelumab monotherapy in patients (pts) with advanced renal cell carcinoma (aRCC) enrolled in the phase 1b JAVELIN Solid Tumor trial


22 Oct 2018


Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care


Tumour Site

Renal Cell Cancer


Ulka Vaishampayan


Annals of Oncology (2018) 29 (suppl_8): viii303-viii331. 10.1093/annonc/mdy283


U.N. Vaishampayan1, P. Schöffski2, A. Ravaud3, C. Borel4, T. Song5, S. Guenther6, J. Grewal7, J. Gulley8

Author affiliations

  • 1 Oncology, Karmanos Cancer Institute, 48201-2013 - Detroit/US
  • 2 Department Of General Medical Oncology, University Hospitals Leuven, 3000 - Leuven/BE
  • 3 Oncologie, Groupe Hospitalier Saint André - Hôpital St. André, 33000 - Bordeaux/FR
  • 4 Oncologie Médicale, Centre Paul Strauss, 67065 - Strasbourg/FR
  • 5 Biostatistics, EMD Serono, Billerica/US
  • 6 Medical Affairs, Merck KGaA, Darmstadt/DE
  • 7 Immuno-oncology, EMD Serono, Billerica/US
  • 8 Genitournary Malignancies Branch, National Cancer Institute, 20892 - Bethesda/US

Abstract 4478


Avelumab is a human anti–PD-L1 IgG1 monoclonal antibody approved for the treatment of metastatic Merkel cell carcinoma and, in the US/Canada, advanced urothelial carcinoma progressed on platinum therapy. Here, we report phase 1b data from the multicohort JAVELIN Solid Tumor trial (NCT01772004) in pts with aRCC treated with avelumab monotherapy in either the 1L or 2L setting.


Eligible pts in the 1L subgroup had measurable aRCC with a clear cell component and ECOG ≤1; in the 2L subgroup, pts must have progressed after 1 prior line of therapy. All pts received avelumab 10 mg/kg IV Q2W until disease progression, unacceptable toxicity, or withdrawal. Assessments included objective response rate (ORR; according to RECIST v1.1 per investigator), progression-free survival (PFS), overall survival (OS), and safety.


As of 27 April 2017, 82 pts received avelumab: 62 pts as 1L (median follow-up, 14.2 mo [range, 6-17 mo]; 24 pts remained on treatment) and 20 pts as 2L (median follow-up, 22.1 mo [range, 16-23 mo]; 2 pts remained on treatment). Efficacy data are summarized below. The rates of treatment-related adverse events (TRAEs) were 75.8% (grade ≥3, 12.9%) and 70.0% (grade ≥3, 5.0%) in the 1L and 2L subgroups, respectively. The only grade ≥3 TRAE that occurred in > 1 pt was elevated lipase (n = 4); no TR deaths or unexpected immune-related TRAEs occurred. Updated data will be presented.Table: 877P

1L (n = 62)2L (n = 20)
Response ORR (95% CI), % Duration of response, median (95% CI), mo16.1 (8.0-27.7) 10.4 (2.8-10.4)10.0 (1.2-31.7) NE (6.9-NE)
PFS Median (95% CI), mo 6-mo rate (95% CI), %8.3 (5.5-9.7) 55.7 (41.9-67.4)5.6 (2.3-8.2) 44.9 (21.9-65.6)
OS Median (95% CI), mo 12-mo rate (95% CI), %NE 85.9 (73.4-92.8)16.9 (8.3-NE) 65.0 (40.3-81.5)

NE, not estimable.


Avelumab, administered either as 1L or 2L monotherapy, showed durable responses, promising survival outcomes, and an acceptable safety profile in pts with aRCC. These data, as well as those recently reported from a phase 1b trial investigating the 1L combination of avelumab + axitinib (VEGF pathway inhibitor; NCT02493751), provide a rationale for the randomized, phase 3 JAVELIN Renal 101 trial (NCT02684006) comparing avelumab + axitinib with sunitinib as 1L treatment for pts with aRCC.

Clinical trial identification


Legal entity responsible for the study

Merck KGaA, Darmstadt, Germany.


This trial was sponsored by Merck KGaA, Darmstadt, Germany and is part of an alliance between Merck KGaA and Pfizer.

Editorial Acknowledgement

Medical writing support was provided by ClinicalThinking Inc., Hamilton, NJ, USA.


U.N. Vaishampayan: Consulting fees: Bayer, Exelixis, Novartis, Pfizer, BMS, Takeda; Research funding: Novartis, Exelixis, Pfizer; Honoraria: Sanofi, Pfizer, BMS, Bayer, Medivation, Takeda. P. Schöffski: Financial interests: Daiichi Sankyo, Eisai, Eli Lilly, Medpace, Novartis, Swedish Orphan Biovitrium, 6th Element Capital, Adaptimmune, Amcure, AstraZeneca, Bayer, Blueprint Medicines, BMS, Boehringer Ingelheim, Cristal Therapeutics, Epizyme, Genzyme, Ipsen, Loxo, Nektar, Novartis, Philogen, Piqur Therapeutics, Plexxikon, GSK, PharmaMar, Cobiores nv, Exelixis. C. Borel: Financial interest: Merck, BMS, AstraZeneca, Amgen. T. Song, J. Grewal: Financial interest: EMD Serono. S. Guenther: Financial interest: Merck KGaA. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.